Who are Predxbio's investors?

Predxbio's investors include Central Texas Angel Network, Emerging Ventures, Keiretsu Forum, Newlin Investment Company LLC, NW Angel.

How much funding has Predxbio raised?

Predxbio has disclosed $2M raised across 5 rounds.

Where is Predxbio headquartered?

Predxbio is headquartered in Pittsburgh, US.

Predxbio

Pittsburgh, US · Founded 2017 · 5 known investors

Find your way into Predxbio

559 people in our graph share verified history with the Predxbio team — schools, employers, funds. One of them is your warm intro.

Ken Howardunlockedknows Jeffrey L. Fine · together at UPMC (overlapped)

knows the team · via University of Pittsburgh School of Medicine

knows the team · via The Ohio State University College of Medicine

×9knows the team · via University of Pittsburgh

PredxBio develops tissue analysis software that uses spatial multi-omics data to identify biomarkers and inform drug development decisions. The platform helps pharmaceutical and biotech companies move from exploratory tissue analysis to clinical development with explainable insights about cell states, microenvironments, and therapeutic response patterns.

AI & Machine Learning Biotech Digital Health Healthtech Medical Devices

Founders & leadership

Predxbio was founded in 2017 by S. Chakra Chennubhotla, D. Lansing Taylor, Michael J. Becich, and Jeffrey L. Fine.

S. Chakra ChennubhotlaChief Executive Officer & Co-founderExecutive Officer, Director at SpIntellx

D. Lansing Taylor Co-founder, Scientific & Business AdvisorDr. Taylor has held academic positions at Harvard, Carnegie Mellon University, and the University of Pittsburgh, and has founded or led multiple biotechnology companies including Cellomics, Cellumen, Cernostics, and Biosystics. His expertise spans quantitative systems pharmacology, patient-derived cellular models, and spatial omics approaches applied to drug discovery in liver disease and oncology.

Michael J. BecichCo-founder, Scientific Advisor

Jeffrey L. Fine Co-founder, Scientific AdvisorJeffrey L. Fine is co-founder and scientific advisor at PredxBio. He has expertise in explainable AI, pathology informatics, surgical pathology, and breast and gynecological cancer research.

B. Dusty Majumdar Chief Executive OfficerB. Dusty Majumdar is Chief Executive Officer of PredxBio, a spatial biology platform company. Previously, he held commercial and product leadership roles at IBM Watson Health, GE HealthCare, Exact Sciences, and ASCO, with experience across AI-enabled health platforms, precision oncology, medical imaging, and genomics.

Joe CamarattaSr. VP Business Development

Bruce VP Software EngineeringBruce holds a background in quantitative systems pharmacology and computational pathology, with prior academic roles at Harvard, Carnegie Mellon University, and the University of Pittsburgh, as well as experience founding and leading biotechnology companies including Cellomics, Cellumen, Cernostics, and Biosystics. He is VP of Software Engineering at PredxBio, which develops tissue analysis software using spatial multi-omics data to identify biomarkers for drug development.

Board

William Newlin Board directorChairman at Newlin Investment Company LLC

Investors · 5

Central Texas Angel Networklisted by Central Texas Angel NetworkAustin

Emerging Ventureslisted by Emerging VenturesLos Angeles · $100K – $500K

How we know: Emerging Ventures's portfolio page · Not right? Tell us

Keiretsu Forumlisted by Keiretsu ForumSan Francisco · $250K – $2M

Newlin Investment Company LLClisted by Newlin Investment Company LLCPittsburgh · $100K – $3M

How we know: funding news · Not right? Tell us

NW Angellisted by NW AngelSeattle

Reported raises · per SEC filings

Form D private placements

$2M disclosed across 5 rounds · 2018–2023

▶$601.3KraisedAug 2023 · 11 investors · Other Health Care

Rule 506(b)